Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth

Cancer Cell

Volumn 22, Issue 1, 2012, Pages 80-90

  Wilson, Nicholas S ^a   Yang, Annie ^a   Yang, Becky ^a   Couto, Suzana ^a   Stern, Howard ^a   Gogineni, Alvin ^a   Pitti, Robert ^a   Marsters, Scot ^a   Weimer, Robby M ^a   Singh, Mallika ^a   Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CD45 ANTIGEN; DEATH RECEPTOR 5; DULANERMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

MUS;

EID: 84863763517     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.05.014     Document Type: Article

References (40)

1. Abdulghani J., El-Deiry W.S. TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 2010, 14:1091-1108.
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
3. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
4. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008, 19:325-331.
5. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 2008, 118:1979-1990.
6. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104:155-162.
7. Baguley B.C. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer. Clin. Lung Cancer 2011, 12:81-86.
8. Brey E.M., Lalani Z., Johnston C., Wong M., McIntire L.V., Duke P.J., Patrick C.W. Automated selection of DAB-labeled tissue for immunohistochemical quantification. J. Histochem. Cytochem. 2003, 51:575-584.
9. Chan J., Prado-Lourenco L., Khachigian L.M., Bennett M.R., Di Bartolo B.A., Kavurma M.M. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ. Res. 2010, 106:1061-1071.
10. Chen P.L., Easton A.S. Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem. Biophys. Res. Commun. 2010, 391:936-941.
11. Corti A., Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann. N Y Acad. Sci. 2004, 1028:104-112.
12. Dejana E. Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol. 2004, 5:261-270.
13. Diehl G.E., Yue H.H., Hsieh K., Kuang A.A., Ho M., Morici L.A., Lenz L.L., Cado D., Riley L.W., Winoto A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004, 21:877-889.
14. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J., Sharkey J., Anthony D.A., Banks K.M., Haynes N.M., Gangatirkar P., Stanley K., et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. USA 2008, 105:11317-11322.
15. Hallmann R., Mayer D.N., Berg E.L., Broermann R., Butcher E.C. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev. Dyn. 1995, 202:325-332.
16. Haynes N.M., Hawkins E.D., Li M., McLaughlin N.M., Hämmerling G.J., Schwendener R., Winoto A., Wensky A., Yagita H., Takeda K., et al. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J. Immunol. 2010, 185:532-541.
17. Heath V.L., Bicknell R. Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol. 2009, 6:395-404.
18. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., Novotny W., Goldwasser M.A., Tohnya T.M., Lum B.L., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28:2839-2846.
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
20. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
21. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
22. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
23. Lara P.N., Douillard J.Y., Nakagawa K., von Pawel J., McKeage M.J., Albert I., Losonczy G., Reck M., Heo D.S., Fan X., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:2965-2971.
24. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 2001, 7:383-385.
25. Li J.H., Kirkiles-Smith N.C., McNiff J.M., Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 2003, 171:1526-1533.
26. Lorusso P.M., Boerner S.A., Hunsberger S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?. J. Clin. Oncol. 2011, 29:2952-2955.
27. Mahajan S., Dammai V., Hsu T., Kraft A.S. Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. Carcinogenesis 2008, 29:1734-1741.
28. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
29. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 2007, 7:803-815.
30. Seki N., Hayakawa Y., Brooks A.D., Wine J., Wiltrout R.H., Yagita H., Tanner J.E., Smyth M.J., Sayers T.J. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003, 63:207-213.
31. Siemann D.W., Chaplin D.J., Walicke P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs 2009, 18:189-197.
32. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., Thompson J.D., Cheng J.H., Bou Reslan H., Ho C.C., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28:585-593.
33. Strasser A., O'Connor L., Dixit V.M. Apoptosis signaling. Annu. Rev. Biochem. 2000, 69:217-245.
34. Takeda K., Yamaguchi N., Akiba H., Kojima Y., Hayakawa Y., Tanner J.E., Sayers T.J., Seki N., Okumura K., Yagita H., Smyth M.J. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 2004, 199:437-448.
35. Tang D.G., Chen Y.Q., Newman P.J., Shi L., Gao X., Diglio C.A., Honn K.V. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J. Biol. Chem. 1993, 268:22883-22894.
36. ten Hagen T.L., Seynhaeve A.L., Eggermont A.M. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol. Rev. 2008, 222:299-315.
37. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., Gejyo F., Okumura K., Yagita H., Smyth M.J. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 2006, 12:693-698.
38. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
39. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
40. Yang A., Wilson N.S., Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin. Cell Biol. 2010, 22:837-844.